These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 34571271)

  • 1. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
    Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
    Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
    Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
    J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanoparticle-mediated blockade of CXCL12/CXCR4 signaling enhances glioblastoma immunotherapy: Monitoring early responses with MRI radiomics.
    Wei R; Li J; Lin W; Pang X; Yang H; Lai S; Wei X; Jiang X; Yuan Y; Yang R
    Acta Biomater; 2024 Mar; 177():414-430. PubMed ID: 38360292
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Doxorubicin and siRNA-PD-L1 co-delivery with T7 modified ROS-sensitive nanoparticles for tumor chemoimmunotherapy.
    Wan WJ; Qu CX; Zhou YJ; Zhang L; Chen MT; Liu Y; You BG; Li F; Wang DD; Zhang XN
    Int J Pharm; 2019 Jul; 566():731-744. PubMed ID: 31212055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. siRNA Nanoparticle Targeting PD-L1 Activates Tumor Immunity and Abrogates Pancreatic Cancer Growth in Humanized Preclinical Model.
    Jung JY; Ryu HJ; Lee SH; Kim DY; Kim MJ; Lee EJ; Ryu YM; Kim SY; Kim KP; Choi EY; Ahn HJ; Chang S
    Cells; 2021 Oct; 10(10):. PubMed ID: 34685714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor immunosuppression relief via acidity modulation combined PD-L1 siRNA for enhanced immunotherapy.
    Tang Y; Chang Q; Chen G; Zhao X; Huang G; Wang T; Jia C; Lu L; Jin T; Yang S; Cao L; Zhang X
    Biomater Adv; 2023 Jul; 150():213425. PubMed ID: 37084635
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multifunctional Redox-Responsive Nanoplatform with Dual Activation of Macrophages and T Cells for Antitumor Immunotherapy.
    Zhang W; Liu X; Cao S; Zhang Q; Chen X; Luo W; Tan J; Xu X; Tian J; Saw PE; Luo B
    ACS Nano; 2023 Aug; 17(15):14424-14441. PubMed ID: 37498878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stimuli-responsive nanoparticles for the codelivery of chemotherapeutic agents doxorubicin and siPD-L1 to enhance the antitumor effect.
    Zhou YJ; Wan WJ; Tong Y; Chen MT; Wang DD; Wang Y; You BG; Liu Y; Zhang XN
    J Biomed Mater Res B Appl Biomater; 2020 May; 108(4):1710-1724. PubMed ID: 31746127
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.
    Mu X; Zhang M; Wei A; Yin F; Wang Y; Hu K; Jiang J
    Nanoscale; 2021 May; 13(19):8998-9008. PubMed ID: 33973580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-inhibition of the TGF-β pathway and the PD-L1 checkpoint by pH-responsive clustered nanoparticles for pancreatic cancer microenvironment regulation and anti-tumor immunotherapy.
    Wang Y; Gao Z; Du X; Chen S; Zhang W; Wang J; Li H; He X; Cao J; Wang J
    Biomater Sci; 2020 Sep; 8(18):5121-5132. PubMed ID: 32820750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineered Small Extracellular Vesicles as a FGL1/PD-L1 Dual-Targeting Delivery System for Alleviating Immune Rejection.
    Tsai HI; Wu Y; Liu X; Xu Z; Liu L; Wang C; Zhang H; Huang Y; Wang L; Zhang W; Su D; Khan FU; Zhu X; Yang R; Pang Y; Eriksson JE; Zhu H; Wang D; Jia B; Cheng F; Chen H
    Adv Sci (Weinh); 2022 Jan; 9(3):e2102634. PubMed ID: 34738731
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GSH/pH dual response drug delivery system for photothermal enhanced gene-immunotherapy.
    Ma T; Li W; Ye J; Huang C; Li Y; Qiu H; Yin S
    Nanoscale; 2023 Nov; 15(42):16947-16958. PubMed ID: 37779508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
    Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
    Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8
    Guo M; Yuan F; Qi F; Sun J; Rao Q; Zhao Z; Huang P; Fang T; Yang B; Xia J
    J Transl Med; 2020 Aug; 18(1):306. PubMed ID: 32762721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint reprogramming via sequential nucleic acid delivery strategy optimizes systemic immune responses for gastrointestinal cancer immunotherapy.
    Li Z; Liu X; Cai N; Zhou Z; Huang H; Wu Q; Xu L; Zhu WG; Zhang C; Wei Z; Li D
    Cancer Lett; 2024 Sep; 599():217152. PubMed ID: 39094825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint silencing using RNAi-incorporated nanoparticles enhances antitumor immunity and therapeutic efficacy compared with antibody-based approaches.
    Won JE; Byeon Y; Wi TI; Lee CM; Lee JH; Kang TH; Lee JW; Lee Y; Park YM; Han HD
    J Immunother Cancer; 2022 Feb; 10(2):. PubMed ID: 35228265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lipid core-shell nanoparticles co-deliver FOLFOX regimen and siPD-L1 for synergistic targeted cancer treatment.
    Cao W; Zhang X; Li R; Li Z; Lu A; Yu F; Sun L; Wang J; Wang Z; He H
    J Control Release; 2024 Apr; 368():52-65. PubMed ID: 38368946
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melanoma Cancer Immunotherapy Using PD-L1 siRNA and Imatinib Promotes Cancer-Immunity Cycle.
    Li C; Han X
    Pharm Res; 2020 May; 37(6):109. PubMed ID: 32476052
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment.
    Zhang P; Qin C; Liu N; Zhou X; Chu X; Lv F; Gu Y; Yin L; Liu J; Zhou J; Huo M
    Biomaterials; 2022 May; 284():121518. PubMed ID: 35462305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.